We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+36.64%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$1.35B
AUM Growth
+$446M
Cap. Flow
+$266M
Cap. Flow %
19.74%
Top 10 Hldgs %
44.95%
Holding
104
New
31
Increased
29
Reduced
24
Closed
13

Top Buys

Rank Stock Value
1
TGTX icon
TG Therapeutics
TGTX
+$40.1M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$34.3M
3
ONC
BeOne Medicines Ltd
ONC
+$23.8M
4
BIIB icon
Biogen
BIIB
+$17M
5
KROS icon
Keros Therapeutics
KROS
+$16.2M

Top Sells

Rank Stock Value
1
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$46.4M
2
GSK icon
GSK
GSK
+$39.6M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$26.2M
4
MREO
Mereo BioPharma
MREO
+$24.2M
5
VKTX icon
Viking Therapeutics
VKTX
+$16.4M

Sector Composition

Rank Sector Weight
1 Healthcare 84.45%
2 Consumer Staples 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRMD icon
26
iRadimed
IRMD
$1.17B
$15.9M 1.18%
361,630
-281,576
-44% -$12.4M
BIIB icon
27
Biogen
BIIB
$30B
$15.7M 1.17%
+72,800
New +$17M
KRYS icon
28
Krystal Biotech
KRYS
$9.59B
$15M 1.11%
84,100
+44,100
+110% +$6.13M
PCVX icon
29
Vaxcyte
PCVX
$8.39B
$14.2M 1.05%
207,750
-207,700
-50% -$14.4M
BCAB icon
30
BioAtla
BCAB
$5.68M
$14M 1.04%
81,304
– –
GSK icon
31
GSK
GSK
$104B
$13.7M 1.02%
319,217
-959,323
-75% -$39.6M
RIGL icon
32
Rigel Pharmaceuticals
RIGL
$746M
$13.7M 1.02%
924,199
-20,059
-2% -$270K
ENGN icon
33
enGene Therapeutics
ENGN
$121M
$13.6M 1.01%
+800,000
New +$9.79M
NARI
34
DELISTED
Inari Medical, Inc. Common Stock
NARI
$13.3M 0.99%
+277,000
New +$14.8M
NVCR icon
35
NovoCure
NVCR
$1.84B
$10.9M 0.81%
695,759
+394,759
+131% +$5.81M
TNGX icon
36
Tango Therapeutics
TNGX
$4.84B
$10.7M 0.8%
1,350,145
+503,000
+59% +$5.39M
APLT
37
DELISTED
Applied Therapeutics
APLT
$10.6M 0.79%
1,564,916
+1,104,123
+240% +$4.96M
ACLX
38
DELISTED
Arcellx
ACLX
$10.4M 0.77%
150,000
-9,000
-6% -$571K
ENTA icon
39
Enanta Pharmaceuticals
ENTA
$389M
$10.1M 0.75%
+580,546
New +$7.68M
NUVL
40
DELISTED
Nuvalent
NUVL
$9.71M 0.72%
129,288
-193,600
-60% -$15.4M
IMUX icon
41
Immunic
IMUX
$198M
$9.63M 0.71%
729,301
+699,301
+2,331% +$9.09M
CGON icon
42
CG Oncology
CGON
$6.58B
$9.56M 0.71%
+217,871
New +$8.9M
INBX
43
DELISTED
Inhibrx, Inc. Common Stock
INBX
$9.36M 0.7%
267,871
+252,871
+1,686% +$9.22M
PHVS icon
44
Pharvaris
PHVS
$2.44B
$9.29M 0.69%
401,901
+184,505
+85% +$4.9M
YMAB
45
DELISTED
Y-mAbs Therapeutics
YMAB
$9.28M 0.69%
570,982
+413,800
+263% +$5.58M
MRUS
46
DELISTED
Merus
MRUS
$8.81M 0.65%
195,577
-107,000
-35% -$4.34M
SNDX icon
47
Syndax Pharmaceuticals
SNDX
$1.76B
$8.78M 0.65%
369,000
-145,000
-28% -$3.23M
MREO
48
Mereo BioPharma
MREO
$47.7M
$8.64M 0.64%
2,616,953
-7,160,466
-73% -$24.2M
IMVT icon
49
Immunovant
IMVT
$8.06B
$8.55M 0.63%
264,650
-52,400
-17% -$1.91M
THTX
50
DELISTED
Theratechnologies
THTX
$7.97M 0.59%
4,801,376
– –
1
2
3 4 5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return

Soleus Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, Soleus Capital Management held 104 positions worth $1.35B, up 50% from $901M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Soleus Capital Management deployed $266M of net new capital in Q1 2024, opening 31 new positions and adding to 29 existing holdings. Its largest new stake was BeOne Medicines Ltd: 148,100 shares worth $23.2M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 100% a quarter earlier, followed by Consumer Staples.

On the sell side, the largest reduction was GSK, an estimated $39.6M trimmed.

  • Soleus Capital Management's largest Q1 2024 buy was BeOne Medicines Ltd: 148,100 shares worth $23.2M.
  • Soleus Capital Management added most to TG Therapeutics in Q1 2024, an estimated $40.1M increase.
  • Soleus Capital Management's biggest Q1 2024 reduction was GSK, cutting an estimated $39.6M.
  • Soleus Capital Management fully exited RayzeBio, Inc. Common Stock in Q1 2024, selling an estimated $46.4M.
  • Soleus Capital Management's ten largest holdings make up 45% of its $1.35B portfolio in Q1 2024.
  • Soleus Capital Management opened 31 new positions and closed 13 in Q1 2024.
  • Soleus Capital Management's portfolio value rose 50% quarter-over-quarter to $1.35B.

Based on Soleus Capital Management's 13F filing for Q1 2024, filed 15 May 2024.